Statutory action
An enacted law requires the exact chapter law, effective date, and operative language. A press release or bill summary is not the final legal text.
A focused view of state legislative and appropriations activity related to ibogaine, public research, and policy proposals—read alongside the broader U.S. ibogaine legal context, not as a substitute for current official records.
State action can signal interest in research, study, or funding. It does not make ibogaine federally lawful, available for general clinical use, or appropriate for self-directed treatment. This page distinguishes those boundaries and flags where primary-source verification matters most.
Status notes are intended as orientation. Verify bill numbers, amendment language, enactment dates, fiscal conditions, and effective dates through the relevant official state legislative portal.
The useful distinction is between a completed state action, an appropriations direction, a research authorization, and a proposal still moving through committees. Each has a different legal effect and a different evidentiary trail.
An enacted law requires the exact chapter law, effective date, and operative language. A press release or bill summary is not the final legal text.
Budget language may direct study, planning, or grant activity. Funding alone does not revise controlled-substance scheduling or create a treatment authorization.
Filed measures can be amended, stalled, substituted, or withdrawn. A tracker should name the bill and session, then defer to the official status history.
Ibogaine remains listed in Schedule I under federal law. The DEA’s controlled-substances schedule identifies ibogaine among federally controlled substances, which means a state study directive or research appropriation does not displace federal requirements.
For the underlying framework, the federal scheduling statute is the relevant starting point. Research pathways involve distinct approvals and institutional responsibilities; they should not be inferred from a state policy announcement.
These notes identify the kind of state action that merits close attention. They are not a substitute for session records, enrolled bills, conference reports, agency guidance, or current appropriations documents.
Texas has drawn attention for legislative interest in ibogaine-related research and public funding. The legally meaningful questions are whether a measure passed, what agency or institution is named, whether money was actually appropriated, and what conditions govern use of those funds. Start with the Texas Legislature Online bill record for current text, history, companion measures, and final actions.
A research appropriation can support investigation or planning without creating a state pathway for ordinary possession, dispensing, or treatment. For broader safety context around withdrawal claims, see the independent discussion of ibogaine and withdrawal considerations.
Arizona policy discussions and proposed measures should be read at the bill level: sponsor, committee referral, substitute text, vote history, and session end status can all change the meaning of a headline. The Arizona Legislature’s official portal is the appropriate place to verify bill numbers and dates before treating a proposal as law.
Questions about formulations should not be used to infer legal status. A separate overview of ibogaine HCl context may help distinguish terminology, while legal conclusions should remain tied to primary legal sources.
Elsewhere, interest may appear in a committee hearing, a research resolution, an agency request, or a budget line rather than a standalone ibogaine statute. The National Conference of State Legislatures’ overview of state legislatures is a useful reminder that sessions, procedures, and bill-status conventions vary by jurisdiction.
For people comparing international settings, perspectives beyond Mexico should be kept analytically separate from the question of U.S. state law.
“A state’s decision to study or fund research is not the same as changing federal scheduling, approving a medicine, or authorizing a clinic.”
No. Funding can support a defined research or policy purpose, but it does not itself supersede federal Schedule I status or establish general access. The Controlled Substances Act overview provides background on the federal framework, while current legal interpretation should rest on official text.
Confirm the state, legislative session, bill number, latest action, current text, and whether the measure became law. If the claim concerns services or facilities, consult the site’s scope and information pathways before treating a policy proposal as a treatment option.
Not by itself. Policy interest and research authorization are different from clinical evidence, individual screening, or medical advice. For terminology around research compounds, the material on ibogaine and MMA discussion should be read as context, not as a clinical recommendation.
Botanical terminology, extraction claims, and legal classification can be confused in public discussion. Information on iboga plant seeds and terminology does not establish a lawful U.S. possession or use pathway; verify the applicable law and current official records.
Where public discussion turns to treatment locations, distinguish legal status from marketing claims and verify regulatory facts independently. The independent directory context at ibogaine clinic information should be approached with the same caution: it does not replace medical, legal, or regulatory review.
Research & Policy FAQ